Understanding the effects of chronic benzodiazepine use in depression: a focus on neuropharmacology
The DOI matches its Crossref record; 173 of the 178 references it cites were found in a registry or an index.
Abstract
Benzodiazepines are frequently prescribed on an ongoing basis to individuals with depression, mainly to alleviate anxiety or insomnia, despite current guideline recommendations that continuous use should not exceed 4 weeks. Currently, there are no efficacy trials published beyond 8 weeks. Several antidepressant trials demonstrate that the concomitant use of a benzodiazepine is associated with poorer depressive outcomes and functional status; however, it is unclear why this is the case. Patients with depression receiving a benzodiazepine may reflect a more ill or high anxiety group, although even within anxiety disorders, the use of a benzodiazepine is associated with poorer outcomes. The neuroadaptive consequences of long-term benzodiazepine use may be a factor underlying these findings. Chronic benzodiazepine use results in decreased gamma-aminobutyric acid and monoaminergic function, as well as interference with neurogenesis, which are all purported to play a role in antidepressant efficacy. This review will discuss the oppositional neuropharmacological interactions between chronic benzodiazepine use and antidepressant mechanism of action, which could result in reduced antidepressant efficacy and function in depression.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“First, BZD have been associated with worse mood outcomes long-term and may increase suicidality in vulnerable patients with other psychiatric risk-factors.141, 142, 143, 144”
Citations
Cites
Nestler, E. J., Barrot, M., DiLeone, R. J., Eisch, A. J., Gold, S. J., & Monteggia, L. M. (2002) · Neuron · doi:10.1016/s0896-6273(02)00653-0 · Cited by 3,217
Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus
Malberg, J. E., Eisch, A. J., Nestler, E. J., & Duman, R. S. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-24-09104.2000 · Cited by 3,111
A molecular and cellular theory of depression
Duman, R. S. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830190015002 · Cited by 2,129
David, D. J., Samuels, B. A., Rainer, Q., Wang, J.-W., Marsteller, D., Mendez, I., Drew, M., Craig, D. A., Guiard, B. P., Guilloux, J.-P., et al. (2009) · Neuron · doi:10.1016/j.neuron.2009.04.017 · Cited by 1,267
GABA regulates synaptic integration of newly generated neurons in the adult brain
Ge, S., Goh, E. L. K., Sailor, K. A., Kitabatake, Y., Ming, G.-L., & Song, H. (2006) · Nature · doi:10.1038/nature04404 · Cited by 1,264
Kennedy, S. H., Lam, R. W., McIntyre, R. S., Tourjman, S. V., Bhat, V., Blier, P., Hasnain, M., Jollant, F., Levitt, A. J., MacQueen, G. M., et al. (2016) · The Canadian Journal of Psychiatry · doi:10.1177/0706743716659417 · Cited by 1,181
Self-citationDuman, R. S., Sanacora, G., & Krystal, J. H. (2019) · Neuron · doi:10.1016/j.neuron.2019.03.013 · Cited by 1,026
BDNF - a key transducer of antidepressant effects
Björkholm, C., & Monteggia, L. M. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.10.034 · Cited by 958
The GABAergic deficit hypothesis of major depressive disorder
Luscher, B., Shen, Q., & Sahir, N. (2011) · Molecular Psychiatry · doi:10.1038/mp.2010.120 · Cited by 934
Koolschijn, P. C. M. P., van Haren, N. E. M., Lensvelt‐Mulders, G. J. L. M., Hulshoff Pol, H. E., & Kahn, R. S. (2009) · Human Brain Mapping · doi:10.1002/hbm.20801 · Cited by 902
Research works printed but not linked: 2
- Furukawa, 2002, Antidepressant and benzodiazepine for major depression., Cochrane Database Syst Rev, 1, CD001026
- Mbomo, 2011, Effect of Mimosa pudica (Linn.) extract on anxiety behavior and GABAergic regulation of 5-HT neuronal activity in the mouse., J Psychopharmacol, 26, 573
Cited by
Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options
Garakani, A., Murrough, J. W., Freire, R. C., Thom, R. P., Larkin, K., Buono, F. D., & Iosifescu, D. V. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.595584 · Cited by 440
Cutler, A. J., Mattingly, G. W., & Maletic, V. (2023) · Translational Psychiatry · doi:10.1038/s41398-023-02514-2 · Cited by 192
Positive affect and reward processing in the treatment of depression, anxiety and trauma
Craske, M. G., Dunn, B. D., Meuret, A. E., Rizvi, S. J., & Taylor, C. T. (2024) · Nature Reviews Psychology · doi:10.1038/s44159-024-00355-4 · Cited by 124
Self-citationLevkovich, I., & Elyoseph, Z. (2023) · Family Medicine and Community Health · doi:10.1136/fmch-2023-002391 · Cited by 83
Brandt, J., Bressi, J., Lê, M.-L., Neal, D., Cadogan, C., Witt-Doerring, J., Witt-Doerring, M., & Wright, S. (2024) · eClinicalMedicine · doi:10.1016/j.eclinm.2024.102507 · Cited by 77
Metadata
- Authors
- Lim, B., Sproule, B. A., Zahra, Z., Sunderji, N., Kennedy, S. H., & Rizvi, S. J.
- Affiliations
- St. Michael's Hospital (CA)
- Centre for Addiction and Mental Health (CA)
- Waypoint Centre for Mental Health Care (CA)
- Corresponding author
- Rizvi, Sakina J.
- Venue
- International Clinical Psychopharmacology
- Published
- 2020-05-25
- Volume
- 35
- Issue
- 5
- Pages
- 243-253
- ISSN
- 0268-1315 (ISSN-L)
- OpenAlex
- W3031969505
- Cited by
- 50
- References
- 178
- Citations by year
- 2026: 8 · 2025: 7 · 2024: 15 · 2023: 10 · 2022: 5 · 2021: 3 · 2020: 2
- FWCI
- 0.65
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- International Clinical Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- chronic benzodiazepine use, depression, antidepressant efficacy, GABAergic function, neurogenesis, anxiety, insomnia, functional outcome
- MeSH terms
- Anxiety, Benzodiazepines, Central Nervous System, Depression, Humans, Anti-Anxiety Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Understanding the effects of chronic benzodiazepine use in depression: a focus on neuropharmacology. https://app.cochat.ai/papers/10.1097/yic.0000000000000316
- The paper
- Lim, B., Sproule, B. A., Zahra, Z., Sunderji, N., Kennedy, S. H., & Rizvi, S. J. (2020). Understanding the effects of chronic benzodiazepine use in depression: a focus on neuropharmacology. International Clinical Psychopharmacology. https://doi.org/10.1097/yic.0000000000000316
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.